Literature DB >> 17638121

Utilities and disutilities for type 2 diabetes treatment-related attributes.

Louis S Matza1, Kristina S Boye, Nicole Yurgin, Jessica Brewster-Jordan, Sally Mannix, Jodi M Shorr, Beth L Barber.   

Abstract

INTRODUCTION: Although cost-utility analyses are frequently used to estimate treatment outcomes for type 2 diabetes, utilities are not available for key medication-related attributes. The purpose of this study was to identify the utility or disutility of diabetes medication-related attributes (weight change, gastrointestinal side effects, fear of hypoglycemia) that may influence patient preference.
METHODS: Patients with type 2 diabetes in Scotland and England completed standard gamble (SG) interviews to assess utility of hypothetical health states and their own current health state. The EQ-5D, PGWB, and Appraisal of Diabetes Symptoms were administered. Construct validity and differences among health states were examined with correlations, t-tests, and ANOVAs.
RESULTS: A total of 129 patients (51 Scotland; 78 England) completed interviews. Mean utility of diabetes without complications was 0.89. Greater body weight was associated with disutility, and lower body weight with added utility (e.g., 3% higher = -0.04; 3% lower = +0.02). Gastrointestinal side effects and fear of hypoglycemia were associated with significant disutility (p < 0.001). SG utility of current health (mean = 0.87) demonstrated construct validity through correlations with patient-reported outcome measures (r = 0.08-0.31). DISCUSSION: The vignette-based approach was feasible and useful for assessing added utility or disutility of medication-related attributes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638121     DOI: 10.1007/s11136-007-9226-0

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  68 in total

1.  A consistency test of the time trade-off.

Authors:  Han Bleichrodt; Jose Luis Pinto; Jose Maria Abellan-Perpiñan
Journal:  J Health Econ       Date:  2003-11       Impact factor: 3.883

2.  Reliability and validity of the appraisal of diabetes scale.

Authors:  M P Carey; R S Jorgensen; R S Weinstock; R P Sprafkin; L J Lantinga; C L Carnrike; M T Baker; A W Meisler
Journal:  J Behav Med       Date:  1991-02

3.  A cost utility analysis of treatment options for gallstone disease: methodological issues and results.

Authors:  J Cook; J Richardson; A Street
Journal:  Health Econ       Date:  1994 May-Jun       Impact factor: 3.046

4.  Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

5.  Valuing health-related quality of life in diabetes.

Authors:  J Todd Coffey; Michael Brandle; Honghong Zhou; Deanna Marriott; Ray Burke; Bahman P Tabaei; Michael M Engelgau; Robert M Kaplan; William H Herman
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

6.  Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.

Authors:  Adrian Bagust; Sophie Beale
Journal:  Health Econ       Date:  2005-03       Impact factor: 3.046

7.  Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.

Authors:  Lawrence Blonde; George E Dailey; Serge A Jabbour; Charles A Reasner; Donna J Mills
Journal:  Curr Med Res Opin       Date:  2004-04       Impact factor: 2.580

8.  A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes.

Authors:  Sheri L Maddigan; David H Feeny; Jeffrey A Johnson
Journal:  Med Decis Making       Date:  2003 Nov-Dec       Impact factor: 2.583

9.  Fear of hypoglycemia in type 1 (insulin-dependent) diabetic patients.

Authors:  M Costea; C Ionescu-Tîrgovişte; D Cheţa; I Mincu
Journal:  Rom J Intern Med       Date:  1993 Oct-Dec

10.  Methodological issues of patient utility measurement. Experience from two clinical trials.

Authors:  M P Rutten-van Mölken; C H Bakker; E K van Doorslaer; S van der Linden
Journal:  Med Care       Date:  1995-09       Impact factor: 2.983

View more
  47 in total

1.  Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?

Authors:  Akbar K Waljee; Ryan W Stidham; Peter D R Higgins; Sandeep Vijan; Sameer D Saini
Journal:  J Crohns Colitis       Date:  2013-08-12       Impact factor: 9.071

2.  Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

Authors:  Charalampos Tzanetakos; Alexandra Bargiota; Georgia Kourlaba; George Gourzoulidis; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

Review 3.  A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Authors:  Tom W C Lung; Alison J Hayes; Andrew Hayen; Andrew Farmer; Philip M Clarke
Journal:  Qual Life Res       Date:  2011-04-07       Impact factor: 4.147

4.  Diabetes and its impact on health-related quality of life: a life table analysis.

Authors:  Khokan C Sikdar; Peizhong Peter Wang; Don MacDonald; Veerabhadra G Gadag
Journal:  Qual Life Res       Date:  2010-03-27       Impact factor: 4.147

Review 5.  A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

Authors:  Scott Doyle; Andrew Lloyd; Lee Moore; Joshua Ray; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

Review 6.  An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.

Authors:  Anil N Makam; Oanh K Nguyen
Journal:  Circulation       Date:  2017-01-10       Impact factor: 29.690

7.  Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China.

Authors:  Wen Su; Chaoyun Li; Lei Zhang; Ziyi Lin; Jun Tan; Jianwei Xuan
Journal:  Diabetes Ther       Date:  2019-09-03       Impact factor: 2.945

8.  Health-related quality of life in diabetes: The associations of complications with EQ-5D scores.

Authors:  Oddvar Solli; Knut Stavem; I S Kristiansen
Journal:  Health Qual Life Outcomes       Date:  2010-02-04       Impact factor: 3.186

9.  Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Authors:  Meryl Brod; Paul Valensi; Joseph A Shaban; Don M Bushnell; Torsten L Christensen
Journal:  Qual Life Res       Date:  2010-07-04       Impact factor: 4.147

10.  Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.

Authors:  Anushua Sinha; Mangala Rajan; Thomas Hoerger; Len Pogach
Journal:  Diabetes Care       Date:  2010-01-07       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.